Oculo-respiratory syndrome following influenza vaccination: evidence for occurrence with more than one influenza vaccine

Serres, Gaston De; Boulianne, Nicole; Duval, Bernard; Rochette, Louis; Grenier, Jean Luc; Roussel, Renée; Donaldson, Danièle; Tremblay, Mireille; Toth, Eveline; Ménard, Suzanne; Landry, Monique; Robert, Y.

doi:10.1016/s0264-410x(03)00095-1

Cited by 25 publications

(15 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These symptoms reflect many conditions (e.g., hypersensitivity reactions, GBS, pneumonitis) and may also be more common due to confounding by indication, i.e., persons with chronic respiratory conditions are advised to receive TIV. An "oculorespiratory syndrome", defined as respiratory symptoms or facial edema or red eyes within 24 h following receipt of TIV, has been described in Canada [37][38][39][40][41]. However these symptoms have high background rates (3.4% among placebo recipients in one study [41]), and it is difficult to assess their possible association with vaccination from spontaneous reporting.…”

Section: Discussionmentioning

confidence: 99%

Safety of trivalent inactivated influenza vaccines in adults: Background for pandemic influenza vaccine safety monitoring

Vellozzi

Burwen

Dobardzic

et al. 2009

Vaccine

171

122

View full text Add to dashboard Cite

a b s t r a c tIn preparation for pandemic vaccine safety monitoring, we assessed adverse events reported to the Vaccine Adverse Event Reporting System following receipt of trivalent inactivated influenza vaccines among adults from 1990 through 2005. We calculated reporting rates for nonserious, serious, and neurological adverse events. We reviewed reports of recurrent events and deaths, as well as reports identified through advanced signal detection. The most frequently reported events were local reactions and systemic symptoms. Guillain-Barré syndrome was the most frequently reported serious event (0.70 reports per million vaccinations). Adverse event reporting rates have been reasonably constant over time. No new safety concerns emerged after our review of 15 years of post-licensure surveillance data. These findings provide useful information if pandemic vaccine is rapidly distributed and pre-licensure data are limited.Published by Elsevier Ltd. BackgroundInfluenza vaccines are the primary method for the control of influenza and its complications and the most widely used type of vaccine for adults in the United States (US). The US and much of the world is preparing for the use of pandemic influenza vaccines [1]. However, even with extensive planning, limited safety data will be available for these vaccines prior to use. Safety profile highlights of the seasonal trivalent inactivated influenza vaccines (TIV) can provide a background for interpretation of adverse events that can be anticipated if pandemic influenza vaccines must be employed in the future. In addition, special importance for TIV safety monitoring stems from the 1976-1977 influenza season, when a mass vaccination effort in the US against swine influenza was halted after the vaccines appeared to be associated with an elevated risk of Guillain-Barré syndrome (GBS) [2].Placebo-controlled trials among older and healthy young adults have demonstrated that TIV administration is not associated with an increased risk of systemic symptoms (e.g., fever, malaise, myalgia); the most frequent adverse effect following vaccination is pain at the injection site [3] including anaphylaxis can occur [3], but the latter is rare [4]. A pre-licensure study of the recently licensed H5N1 vaccine identified headache, malaise, and myalgia as the most frequent systemic symptoms but also identified these at similar rates among placebo recipients [5]. Clinical trials are generally not large enough to detect rare adverse events. Post-licensure safety data provide examples of adverse event experiences among a larger and more diverse population, and reporting of adverse events following receipt of seasonal TIV to the US Vaccine Adverse Event Reporting System (VAERS) is an important source of this information. We examined 15 years of VAERS data among adults aged ≥18 years to describe patterns of adverse events after seasonal vaccines and to identify possible safety concerns that might merit intensified monitoring or evaluation. Although pandemic influenza vaccines will differ fr...

show abstract

Section: Discussionmentioning

confidence: 99%

Safety of trivalent inactivated influenza vaccines in adults: Background for pandemic influenza vaccine safety monitoring

Vellozzi

Burwen

Dobardzic

et al. 2009

Vaccine

171

122

View full text Add to dashboard Cite

show abstract

“…Vaccination side effects are usually uncommon, ranging from 5% to 35%, and involve local reaction at the injection site and rare systemic manifestations like anaphylactic reactions, Guillain-Barre syndrome, or small-vessel vasculitis. Recently, De Serres et al 10 and others reported on oculorespiratory syndrome as a unique adverse reaction after influenza vaccination. From a Medline database search we found only one case report in the last 20 years of reactive arthritis after influenza vaccination by Biasi et al 11 They reported on an HLA-B27 positive subject (a 32-year-old man) who presented a typical onset of a reactive arthritis 2 weeks after an influenza vaccination.…”

Section: Discussionmentioning

confidence: 99%

Reactive arthritis after influenza vaccination: report of a case

et al. 2005

View full text Add to dashboard Cite

We describe a patient with reactive arthritis (ReA) induced by influenza vaccination. A healthy 79-year-old Japanese man began suffering from migrating polyarthritis 2 days after receiving influenza vaccine. He proved negative for rheumatoid factor, showing no evidence for microbial infections such as Streptoccocci, Chlamydia, or Parbovirus B19. Human leukocyte antigen (HLA) typing analysis revealed positive results for HLA-B54 (22), which is one of the cross-reactive antigens to HLA-B27. His arthritis improved with administration of nonsteroidal anti-inflammatory drugs, and recovery was attained within 6 weeks. Reactive arthritis is a rare adverse effect induced by influenza vaccination; however, it is important that it is recognized by all physicians.

show abstract

“…The presence of viral aggregates in the vaccine can induce the severe adverse effects. Thus, the emergence of the new oculo-respiratory syndrome was detected in 2000-2001 season in adults after immunization with the vaccine that contained a high amount of aggregated unsplit virus particles [44,45]. Viruses that contain the structurally modified HAs are known to become more sensitive to the cleavage with proteolytic enzymes [46].…”

Section: Effect Of the Influenza Virus Stability On The Quality Of Inmentioning

confidence: 99%

Influenza vaccines manufacturing in continuous cell lines: problems and solutions

Romanova¹

2017

Microbiology Independent Research Journal (MIR Journal)

View full text Add to dashboard Cite

In order to decrease the morbidity and mortality caused by seasonal influenza outbreaks, several hundred million vaccine doses are produced worldwide each year. The predominant substrate for the production of the influenza vaccine today is fertilized hen's eggs. The substitution of the technology based on living organisms by the cell culture-based process offers many advantages, including easier scalability and reduced dependence on the availability of eggs. The African green monkey kidney and Madin Darby canine kidney cell lines support the efficient growth of influenza viruses of different subtypes and, therefore, are considered to be the two most promising alternative substrates for the production of the human influenza vaccine.However, the pH of endosomes in both of these cell lines is higher than the pH essential for triggering a conformational change of the hemagglutinin (HA) of human influenza viruses, which enables the viral-cellular membrane fusion. This mismatch gives rise to mutations in the HA that lead to an increase of the optimum pH of HA conformational change. As of a result of these mismatches, the HA, and consequently the whole virus, has reduced stability to low pH and elevated temperatures. The production of a vaccine from less stable virus will lead to an elevated HA content in the low pH conformation that can affect the safety, potency, infectivity, and protective efficacy of the final inactivated and live attenuated influenza vaccines.The main limitations of the cell line-based influenza vaccine technology and the possibilities to preserve the viral stability over the course of influenza vaccine production are discussed in the review.

show abstract

Oculo-respiratory syndrome following influenza vaccination: evidence for occurrence with more than one influenza vaccine

Cited by 25 publications

References 2 publications

Safety of trivalent inactivated influenza vaccines in adults: Background for pandemic influenza vaccine safety monitoring

Safety of trivalent inactivated influenza vaccines in adults: Background for pandemic influenza vaccine safety monitoring

Reactive arthritis after influenza vaccination: report of a case

Influenza vaccines manufacturing in continuous cell lines: problems and solutions

Contact Info

Product

Resources

About